1. Scrip
  2. >>Business
  3. >>Manufacturing

UK Works Its Way Back Into AstraZeneca's Affections To Bag £650m Investment

 
• By Kevin Grogan

Pascal Soriot has been highly critical of the UK's unfriendly business environment and recently decided to invest $360m in a manufacturing facility in Ireland instead. Now, chancellor Jeremy Hunt has tempted the "irrepressible" AstraZeneca CEO back with the promise of a competitive business tax regime.

Speke
The drug giant's site in Speke is set to expand • Source: AstraZeneca

Having, along with other drugmakers, spent much of the last year questioning the attractiveness of the UK for pharma investments, AstraZeneca PLC has now decided to open its wallet at home and invest an extra £650m ($830m) at two of its sites.

The news was unveiled by UK chancellor Jeremy Hunt in the budget who trumpeted "a brand new investment by one of our greatest life science companies, AstraZeneca, led by mon ami, the irrepressible Sir Pascal Soriot

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Gilead Joins Pharma’s US Investment Rush

 
• By Alaric DeArment

The company drew praise from the Trump administration as one of multiple companies announcing multibillion-dollar investments in US manufacturing and R&D.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

More from Business

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Gilead Joins Pharma’s US Investment Rush

 
• By Alaric DeArment

The company drew praise from the Trump administration as one of multiple companies announcing multibillion-dollar investments in US manufacturing and R&D.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).